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https://doi.org/10.1016/j.celrep.2019.11.079SUMMARY
The tumor microenvironment (TME) plays a pivotal
role in cancer progression, and, in ovarian cancer
(OvCa), the primary TME is the omentum. Here, we
show that the diabetes drug metformin alters
mesothelial cells in the omental microenvironment.
Metformin interrupts bidirectional signaling between
tumor and mesothelial cells by blocking OvCa cell
TGF-b signaling and mesothelial cell production
of CCL2 and IL-8. Inhibition of tumor-stromal
crosstalk by metformin is caused by the reduced
expression of the tricarboxylic acid (TCA) enzyme
succinyl CoA ligase (SUCLG2). Through repressing
this TCA enzyme and its metabolite, succinate,
metformin activated prolyl hydroxylases (PHDs),
resulting in the degradation of hypoxia-inducible
factor 1a (HIF1a) in mesothelial cells. Disruption of
HIF1a-driven IL-8 signaling in mesothelial cells by
metformin results in reduced OvCa invasion in an
organotypic 3D model. These findings indicate that
tumor-promoting signaling between mesothelial
and OvCa cells in the TME can be targeted using
metformin.INTRODUCTION
Ovarian cancer (OvCa) is a devastating disease marked by poor
prognosis, as patients typically present after the disease has
spread from the site of origin throughout the peritoneal cavity
(Lengyel, 2010). Metastasis to the peritoneum and omentum
marks a pivotal step for progression of the disease, as it provides
a nutrient-rich tumormicroenvironment (TME) composed of mul-
tiple cell types, with superficial mesothelial cells providing a bar-
rier over other stromal cells, including fibroblasts and adipocytes
(Kenny et al., 2009; Lengyel, 2010). Increasing evidence sug-
gests that bidirectional signaling and nutrient exchange between
cancer cells and stromal cells in the TME is critically important in
supporting cancer growth (Romero et al., 2015).4086 Cell Reports 29, 4086–4098, December 17, 2019 ª 2019 The A
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ated fibroblasts (Gascard and Tlsty, 2016) and adipocytes
(Nieman et al., 2013); however, recently, mesothelial cells have
been observed to promote tumor progression. In OvCa, meso-
thelial cells are reprogrammed and activated toward a mesen-
chymal phenotype by interacting with cancer cells (Fujikake
et al., 2018; Kenny et al., 2014; Rynne-Vidal et al., 2017). These
activated mesothelial cells promote multiple tumorigenic pro-
cesses, including adhesion (Ksiazek et al., 2009; Paku1a et al.,
2018), migration (Paku1a et al., 2018; Rieppi et al., 1999), and in-
vasion (Kenny et al., 2014), through the altered expression of sur-
face adhesionmolecules and their ligands (Cannistra et al., 1993;
Lessan et al., 1999; Miku1a-Pietrasik et al., 2014; Watanabe
et al., 2012), as well as extracellular matrix (ECM) production
and remodeling (Heyman et al., 2010; Kenny et al., 2008; Ksiazek
et al., 2009; Sandoval et al., 2013). The mechanisms by which
mesothelial cell reprogramming occurs are just beginning to be
elucidated, but multiple groups have reported that secreted
transforming growth factor b (TGF-b) induces pro-tumorigenic
changes in mesothelial cells (Falk et al., 2013; Fujikake et al.,
2018; Rynne-Vidal et al., 2017). In OvCa, we have shown in
mesothelial cells that blocking fibronectin signaling downstream
of TGF-b-dependent activation prevented OvCa adhesion and
invasion in vitro and omental colonization in vivo (Kenny et al.,
2014).
Our understanding of the biology of the TME has evolved
quickly; however, translating these discoveries into cancer
treatments directed at vulnerabilities in the TME has been
challenging. While compounds and antibodies have been
identified that target mesothelial cell ECM to prevent OvCa
adhesion in vitro (Kenny et al., 2014), moving even the most
promising TME-directed compound from pre-clinical evidence
to clinical use will require many years. To accelerate the
discovery of cancer therapeutics, a drug-repurposing para-
digm has been proposed whereby compounds already in
use for non-cancer indications are tested for efficacy in
cancer (Corsello et al., 2017; Sleire et al., 2017). Metformin,
a biguanide commonly used for type 2 diabetes, is a leading
drug in this paradigm and is undergoing clinical testing
in several types of cancer (Chae et al., 2016; Litchfield et al.,
2015). A recent trial in epidermal growth factor receptor
(EGFR) mutant lung adenocarcinoma reported increaseduthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Metformin Inhibits Colonization of
the Omentum Ex Vivo and Invasion of the 3D
TME In Vitro
(A) Schematic: ex vivo adhesion of GFP-tagged
HeyA8 OvCa cells to fresh human omental
biopsies from patients without cancer taking met-
formin for type 2 diabetes or control patients not
taking metformin.
(B) Omental explants from control or metformin
patients were seeded with GFP-tagged HeyA8
OvCa cells. Tumor cells were allowed to adhere to
omental explants for 1.5 h before imaging and
quantification (n = 3 patients per group in tripli-
cate). Images are representative and were taken at
103 magnification; scale bar represents 200 mm.
(C and D) Ex vivo adhesion and colonization:
human omental explants were pretreated with
metformin (250 mM) for 72 h before seeding of
GFP-tagged HeyA8 OvCa cells, and the number of
tumor cells that adhered to (1.5 h, C) or colonized
(72 h, D) per omentum were quantified (n = 2 pa-
tients in triplicate for both experiments).
(E) Migration of HeyA8 OvCa cells through trans-
well chamber (15 h) toward omental explants that
had been pretreated with metformin (250 mM, 72
h). During the assay, metformin was removed, and
all media were replaced with serum-free media
containing 0.1% BSA (n = 2 patients in triplicate).
(F) Invasion through 3D organotypic model (36 h)
after seeding of TYKnu OvCa cells. Each cell type
was individually treated with metformin (250 mM,
72 h) before the 3D model was constructed.
HPMC, human primary mesothelial cells; NOF,
normal omental fibroblast; n = 3 patients in tripli-
cate.
(G) Invasion of TYKnu cells through 3Dmodel (36 h)
treated with the indicated compounds: metformin
(1 mM), AMPK inhibitor compound C (CompC,
1 mM), and AMPK activator AICAR (1 mM) (n = 3
patients in triplicate).
Data represent mean values ± SDs. *p < 0.05, **p <
0.01, and ***p < 0.005; n.s., not significant.progression-free survival when metformin was added to treat-
ment with EGFR-tyrosine kinase inhibitors (Arrieta et al.,
2019), further supporting the potential of metformin as a can-
cer treatment and warranting systematic assessment of the
mechanisms of action of the drug in cancer. In OvCa,
we and others have shown in retrospective analyses
that 12%–17% of OvCa patients have diabetes and that
patients with diabetes who use metformin have increased pro-
gression-free survival compared to patients who do not use
metformin (Kumar et al., 2013; Romero et al., 2012). Comple-
menting the retrospective clinical data, in cell culture, metfor-
min has a direct effect on OvCa cells by altering central
carbon metabolism (Liu et al., 2016) and inhibiting viability,
clonogenicity, and invasion (Hart et al., 2019; Litchfield
et al., 2015). Here, we ask whether, beyond the cancer
compartment alone, metformin can be used to target the
TME to make it inhospitable to OvCa seeding and growth.
We also sought to discover any molecular or metabolic path-
ways in the TME that contribute to the potential efficacy of
metformin as a cancer therapeutic.RESULTS
Exposure of the TME to Metformin Reduces Adhesion,
Colonization, and Invasion of OvCa Cells
The microenvironment of the omentum is uniquely conducive to
OvCa metastasis (Lengyel, 2010). To assess the global effect of
metformin on this metastatic site, fresh samples of omentum
were obtained from patients without cancer, and ex vivo adhe-
sion experiments were performed (Figure 1A). Patients taking
metformin for diabetes had remarkably fewer OvCa cells adhere
to the fresh omentum compared with control patients not using
metformin (Figure 1B). Consistent with these results, when
omental explants from patients without diabetes were treated
with metformin before seeding OvCa cells, fewer OvCa cells
were found to adhere to (1.5 h, Figure 1C) or colonize (72 h, Fig-
ure 1D) the omental explants. Similarly, the pretreatment of
omental tissue decreased the number of OvCa cells that migrate
toward the omentum in an invasion assay (Figure 1E). The super-
ficial anatomic layers of the omentum aremade up of mesothelial
cells covering fibroblasts in a collagen-rich ECM (Kenny et al.,Cell Reports 29, 4086–4098, December 17, 2019 4087
Figure 2. Suppression of Mesothelial Cell-Derived CCL2 and IL-8 Is Required for the Inhibition of Invasion In Vitro and the Colonization
Ex Vivo by Metformin
(A) A representative array membranemeasuring cytokines in mouse omentum. Mice were treated with or without metformin for 3 weeks before the intraperitoneal
(i.p.) injection of ID8 tumor cell CM, and the omentum was harvested 72 h later (see Figure S2A for details) (n = 2 mice per group).
(B) Validation of candidate cytokines CXCL1 and CCL2 from (A) using ELISA (n = 8 mice per group).
(C) qRT-PCR of IL-8 mRNA expression in HPMCs exposed to TYKnu OvCa CM (36 h). HPMCs were pretreated with metformin (250 mM) for 72 h before CM
exposure (n = 4 patients in duplicate).
(D) Invasion of TYKnu OvCa cells (36 h) through the 3D model with or without metformin pretreatment of HPMCs (250 mM for 72 h), or simultaneous treatment ±
recombinant human IL-8 protein (150 ng/mL) (n = 2 patients in triplicate).
(legend continued on next page)
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2014). To identify which cell type in the omental TME is respon-
sible for the effect of metformin, we used a 3D organotypic
model constructed with normal omental fibroblasts (NOFs) and
human primary mesothelial cells (HPMCs) (Kenny et al., 2007)
and pretreated OvCa cells and each stromal cell type separately
with metformin before constructing the model. All of the cell
types were responsive to metformin as evidenced by decreased
mitochondrial respiration (Figure S1A), and this dose of metfor-
min was not cytotoxic in any of the cell types tested (Figure S1B).
The results in the 3D organotypicmodel indicate that the effect of
metformin in the ovarian TME is mediated by HPMCs, as only
pretreatment of this cell type reduced the invasion of OvCa cells
(Figures 1F and S1C). The activation of AMP kinase (AMPK) is
one proposed mechanism of the anti-cancer effects of metfor-
min (Rena et al., 2017); however, here, we found the effects of
metformin to be independent of AMPK as the ability of metformin
to inhibit OvCa invasionwas not attenuated by co-treatment with
an AMPK inhibitor, compound C (Zhou et al., 2001), and the
activation of AMPK using 5-aminoimidazole-4-carboxamide
ribonucleotide (AICAR) (Corton et al., 1995) did not recapitulate
the inhibition of OvCa cell invasion observed with metformin
(Figure 1G).Metformin Blocks OvCa Cell Invasion by Decreasing
CCL2 and IL-8 Production
To understand how the effect of metformin on HPMCs inhibits
the invasion of OvCa cells, we first sought to identify HPMC-
derived cytokines that are altered by metformin. Cytokine arrays
were performed on omenta from C57BL/6 mice pretreated
with metformin for 3 weeks before the injection of ID8 murine
OvCa cell conditioned media (CM) into the peritoneal cavity
(experimental design, Figure S2A). Analysis of cytokine arrays
representing 40 cytokines showed that ID8 CM-induced expres-
sion of the CXCL1 and C-C motif chemokine ligand 2 (CCL2)
cytokines in the mouse omentum and that induction of these
cytokines was prevented in mice that had received metformin
(Figure 2A, quantified in Figure S2B). Both cytokines were vali-
dated in an independent cohort of mice by ELISA analysis of
omental samples (Figure 2B). When p53 was stably knocked
down in ID8 cells, CXCL1 and CCL2 were still induced by
OvCa cell CM, but not significantly repressed by metformin
(Figure S2C).
Next, we asked whether the effect of metformin on the cyto-
kines that were noted in mice were also present in human cells.
Murine CXCL1 is functionally homologous to human interleukin 8
(IL-8) (mice do not harbor an IL-8 gene) (Lee et al., 1995), and we
previously showed that IL-8 plays a pivotal role in OvCa cell colo-
nization of the omentum (Nieman et al., 2011). Consistent with
the observation in mice, CM from human OvCa cells increased
IL-8 mRNA expression in HPMCs, and induction of this cytokine(E) qRT-PCR of CCL2 mRNA expression in HPMCs subjected to TYKnu OvCa C
exposure (n = 4 patients in duplicate).
(F) Invasion of TYKnu OvCa cells (36 h) through the 3D model with or without met
recombinant human CCL2 protein (150 ng/mL) (n = 2 patients in triplicate).
(G and H) 3D invasion (G) or omental explant colonization (H): TYKnu OvCa cells e
(CCR2-T94K) were added to the 3D model constructed with HPMCs pretreated w
Data represent mean values ± SDs. #p < 0.09, *p < 0.05, **p < 0.01, and ***p < 0was prevented by metformin (Figure 2C). To understand the
functional significance of IL-8 in the effect of metformin on
OvCa we used the 3D organotypic model to test whether the
candidate cytokines were necessary targets for the inhibition
of OvCa invasion by metformin. In the 3D organotypic model,
in the presence of recombinant IL-8, metformin no longer
inhibited the invasion of OvCa cells, indicating that the inhibition
of OvCa cell invasion by metformin was IL-8 dependent (Fig-
ure 2D). We also assessed the effect of metformin on CCL2
and found that metformin prevented the induction of CCL2
mRNA in HPMCs by OvCa CM (Figure 2E) and that recombinant
CCL2 protein abrogated the ability of metformin to inhibit OvCa
cell invasion in 3D culture (Figure 2F). Lastly, we tested whether
IL-8 and CCL2 signaling specifically in the tumor cells is required
for the effect of metformin. Here, OvCa cells were stably trans-
fected with receptor mutants for IL-8 (CXCR1; Han, 2014) or
CCL2 (CCR2; Alvarez Arias et al., 2003) that maintain constitutive
activity independent of ligand binding (Figure S2D), and the ef-
fect of metformin on invasion through the 3D organotypic model
and colonization of ex vivo omental explants was measured. The
findings show that with constitutive activation of either the IL-8 or
the CCL2 receptor in the OvCa cells, metformin no longer
decreased OvCa invasion in the 3D model or the ex vivo coloni-
zation of omental explants (Figures 2G and 2H, respectively).
These data indicate that the inhibition of IL-8 or CCL2 cytokine
production by HPMCs and the subsequent signaling of these
cytokines in the tumor cells is a requirement for metformin to
impede OvCa invasion in the TME.Metformin Prevents OvCa-Induced Stabilization of
HIF1a in Mesothelial Cells
To obtain a global understanding of the impact of metformin on
omental mesothelial cells exposed to OvCa, we performed unbi-
ased proteomic profiling. The principal-component analysis of
HPMCs co-cultured with OvCa cells clearly distinguished be-
tween metformin-treated and control untreated cells as
numerous proteins were altered by the drug (Figures 3A and
S3A). Enrichment analysis of these proteins revealed that
metformin repressed pathways involved in pro-metastatic
signaling, including hypoxia signaling, ECM remodeling, and
epithelial-to-mesenchymal transition (Table S1). In addition, in
HPMCs co-cultured with OvCa, unsupervised hierarchical clus-
tering confirmed that a majority of hypoxia-related proteins were
downregulated by metformin (Figure 3B). Since hypoxic
signaling pathways lead to stromal cell reprogramming (Ammir-
ante et al., 2014), andwe have identified hypoxia-inducible factor
1a (HIF1a) as a metformin target in OvCa (Hart et al., 2019), we
focused our evaluation on the effect of metformin on HIF1a in
the ovarian TME. Western blotting demonstrated that OvCa
CM increased HIF1a but not HIF2a expression in HPMCs, andM (36 h). HPMCs were pretreated with metformin (250 mM) for 72 h before CM
formin pretreatment of HPMCs (250 mM for 72 h), or simultaneous treatment ±
xpressing constitutively active IL-8 receptor (CXCR1-V247N) or CCL2 receptor
ith metformin (G) or to a human omental explant pretreated with metformin (H).
.005; n.s., not significant.
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Figure 3. Metformin Prevents Tumor-Cell-Induced Stabilization of HIF1a in Mesothelial Cells
(A) Mass spectrometry (MS) analysis of mesothelial cells (HPMCs) co-cultured with OvCa cells and treated with metformin (1 mM, 48 h). Cell lysates were
collected and measured on a Q Exactive HF mass spectrometer, and the quantification of proteins significantly altered by metformin is shown by volcano plot
(Perseus), with the significantly altered proteins highlighted in red. Significance was defined by a false discovery rate (FDR) of 0.05 and an S0 value of 0.05 (n = 4
patients in triplicate).
(B) Unsupervised hierarchical clustering (Perseus) was performed on the dataset from (A), assessing hypoxia-related proteins in HPMCs following exposure to
TYKnu OvCa co-culture in the presence or absence of metformin (1 mM, 48 h) (n = 4 patients per group in triplicate).
(legend continued on next page)
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the increase in HIF1a was prevented by metformin (Figure 3C).
However, when HPMCs were transfected with a constitutively
stable form of HIF1a (P402A/P564A) that escapes hydrolysis-
mediated degradation by prolyl hydroxylases (PHDs) (Jaakkola
et al., 2001), metformin’s reduction in HIF1a expression was
attenuated (Figure 3D). Next, we sought to understand whether
HIF1a signaling played a role in metformin’s inhibition of IL-8
or CCL2 production by HPMCs. It was noted that when HPMCs
overexpress HIF1a, CCL2 and IL-8 mRNA expression is
increased, and metformin no longer represses these cytokines
(Figure 3E).
Our next goal was to understand whether HIF1a is necessary
for the metformin’s inhibition of OvCa invasion in the TME. When
HIF1a was stabilized through competitive inhibition of PHD ac-
tivity withN-oxalylglycine, metformin did not reduce the invasion
of OvCa cells, and the effect of metformin was restored when
PHD activity was rescued using the PHD substrate 2-oxogluta-
rate (Figures 3F and S3B). Likewise, the overexpression of
HIF1a in HPMCs prevented metformin from reducing OvCa cell
invasion in the 3D culture; however, if the IL-8 receptor was in-
hibited using a neutralizing antibody while HIF1a was overex-
pressed in HPMCs, then metformin once again markedly
reduced OvCa invasion (Figure 3G). This finding suggests that
metformin’s inhibition of OvCa invasion in the TME was a result
of HIF1a inhibition in HPMCs and mediated, at least in part, by
downstream IL-8 signaling. To understand the clinical relevance
of the in vitro findings indicating the metformin-targeted hypoxia
in the TME, we analyzed tissue samples from patients. Here, we
obtained fresh omental samples from patients without cancer
who were taking metformin for diabetes and control patients
without diabetes not taking metformin. Omentum from patients
taking metformin had a lower expression of HIF1a and its down-
stream target, carbonic anhydrase IX (CAIX; Giatromanolaki
et al., 2001), compared to omentum from controls (Figure 3H).
We also established a cohort of patients with OvCa (clinical
data described in Table S2). In this cohort, patients with OvCa
takingmetformin for diabetes had lower CAIX protein expression
in both the primary tumor and the omental metastases
compared to patients without diabetes not taking metformin
(Figure 3I).(C) Western blot of HIF1a and HIF2a protein expression in HPMCs following ex
(representative blot from n = 2 patients in duplicate).
(D) Western blot of HIF1a protein expression in HPMCs expressing constitutivel
sentative blot from n = 2 patients in duplicate).
(E) qRT-PCR of IL-8 (left) and CCL2 (right) mRNA expression in HPMCs transfec
(1 mM) (n = 2 patients in duplicate).
(F) Invasion of TYKnu OvCa cells (36 h) in 3D culture with metformin (pretreatment
and 2-oxoglutarate (2-oxo, 5 mM) (n = 2 patients per group in triplicate).
(G) Invasion of TYKnu OvCa cells (36 h) in 3D culture containing control or HPMCs
(pretreatment of HPMCs with 250 mM for 72 h), with concurrent exposure to IL-8
patients in duplicate).
(H) Western blot of HIF1a and CAIX expression in normal/benign omental expla
without diabetes not using metformin. Right side, densitometry (area under the cu
normalized to vinculin (n = 3 patients per group in duplicate).
(I) CAIX immunohistochemical staining in primary ovarian and omental tumors from
diabetic patients with OvCa not taking metformin. Quantification of primary tumo
(n = 15 and 12 for control and metformin, respectively) was performed using Ima
fication; scale bar represents 100 mm.
Data represent mean values ± SDs. *p < 0.05, **p < 0.01, ***p < 0.005, and ****pMesothelial Cell SUCLG2 Is Repressed by Metformin to
Prevent Metabolically Driven HIF1a Stabilization
Given that HIF1a protein expression is stabilized by excess
tricarboxylic acid (TCA) intermediates (Selak et al., 2005), and
we have shown that metformin alters TCA metabolism in OvCa
(Liu et al., 2016), we hypothesized that metformin regulates
TCA intermediates in HPMCs to prevent the induction of HIF1a
expression. As a first step in testing this hypothesis, we sought
to understand whether metformin changed the baseline protein
expression and metabolic state of HPMCs independent of the
presence of cancer cells. An integrated metabolomic and prote-
omic analysis of OvCa-naive HPMCs treated withmetformin was
performed. In the metabolomics experiment, several metabo-
lites in HPMCswere altered bymetformin, and principal-compo-
nent analysis (PCA) showed a clear separation of the metabolic
profiles in metformin-treated and -untreated HPMCs (Figure 4A;
Table S3). In a parallel proteomic experiment, PCA showed a
clear separation of the proteomic profile of metformin-treated
and -untreated HPMCs (Figure 4B; Table S4). Integrating theme-
tabolomic and proteomic datasets using joint pathway analysis
revealed that metformin altered metabolites and proteins
involved in cell metabolism—most prominently, the TCA cycle,
but also amino acid and nucleotide metabolism (Figure S4A).
Further analysis of specific metabolites showed that in metfor-
min-treated HPMCs, there were lower levels of succinate and
fumarate and malate downstream of succinate; conversely,
there was an increase in one of the primary carbon sources of
succinate, glutamine (Figure 4C; Table S3). Analysis of the
proteomic dataset identified inhibition of the b subunit of succi-
nate-coenzyme A (CoA) ligase (SUCLG2) in metformin-treated
HPMCs (Figure 4D); this is the enzyme subunit responsible for
the guanosine diphosphate (GDP)-dependent conversion of
succinyl-CoA to succinate (Johnson et al., 1998; Ostergaard,
2008). A reduction in both SUCLG2 protein and mRNA expres-
sion with metformin treatment was validated by western blot
and qRT-PCR, respectively (Figure S4B). The majority of the
other TCA enzymes were not markedly inhibited by metformin
(Figure S4C).
Since succinate can inhibit PHD activity and thus stabilize HIF
expression (Koivunen et al., 2007; Selak et al., 2005), we askedposure to TYKnu OvCa co-culture in the presence of metformin (1 mM, 48 h)
y stable HIF1a (P402A/P564A substitutions) ± metformin (1 mM, 48 h) (repre-
ted with constitutively stable HIF1a (P402A/P564A) with or without metformin
of HPMCs with 250 mM for 72 h) in the presence of N-oxalylglycine (OG, 1 mM)
expressing constitutively stable HIF1a (P402A/P564A) treated with metformin
RA/CXCR1 neutralizing antibody (150 ng/mL) during the invasion assay (n = 2
nts from patients using metformin for diabetes compared to control patients
rve [AUC]) of western immunoblot bands of HIF1a and CAIX was quantified and
patients with OvCa who were using metformin for diabetes compared to non-
r (n = 15 and 18 for control and metformin, respectively) or omental metastasis
geScope software. Images are representative and were taken at 203 magni-
< 0.001; n.s., not significant.
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Figure 4. Metformin Represses SUCLG2 and TCA Intermediates to Inhibit HIF1a in Mesothelial Cells
(A) Metabolomics. MS of metabolites extracted frommesothelial cells (HPMCs) treated with metformin (1 mM, 48 h) were analyzed using a two-sided t test with a
FDR of 0.25 and an S0 value of 0.125. Left: volcano plot showing significant metabolites by red dots (n = 2 patients in duplicate). Right: principal-component
analysis (PCA) assessing metabolite profiles of HPMCs treated with metformin compared to control. Open circles represent each group (n = 2 patients in
duplicate).
(B) Proteomics. MS of proteins extracted from HPMCs treated with metformin were analyzed using a two-sided t test with an FDR of 0.05 and an S0 value of 0.1.
Left: volcano plot showing significant proteins by red dots (n = 4 patients in triplicate). Right: PCA assessing protein profiles of HPMCs treated with metformin
compared to control. Open circles represent each group (n = 4 patients in triplicate).
(C) Relative MS intensity of TCA metabolites in HPMCs treated with metformin from (A) was analyzed using a paired t test.
(D) Relative protein expression of the TCA enzyme SUCLG2 in HPMCs treated with metformin from (B) was analyzed using a paired t test.
(E) Western blot of HIF1a expression. HPMCs treated with metformin (250 mM, 72 h) followed by the addition of TYKnu OvCa CM ± succinate (suc, 5 mM)
(representative blot from n = 2 patients in duplicate).
(F) Prolyl hydroxylase (PHD) activity using a GFP reporter construct. A GFP-tagged HIF1a oxygen-dependent degradation domain construct (ODD-GFP) was
expressed in HPMCs; cells were then treated with TYKnu OvCa CM ± metformin (1 mM) ± succinate (suc, 5 mM) for 16 h. An increased GFP signal indicates
depleted PHD activity (n = 2 patients in duplicate).
(legend continued on next page)
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whether succinate could reverse the effect of metformin on
HIF1a in HPMCs exposed to OvCa CM. Western blotting
demonstrated that in the presence of succinate, metformin no
longer inhibited OvCa CM-induced HIF1a protein expression in
HPMCs (Figure 4E). To understand this finding further, we
used a GFP reporter of the HIF1a oxygen-dependent degrada-
tion (ODD) domain. Hydroxylation of the reporter by active
PHD results in lysosomal degradation of the reporter and thus
suppressed the GFP signal; therefore, the ODD-GFP signal is
inversely correlated with PHD activity (Yan et al., 2007). Mirroring
the findings in the HIF1a western blot, the results using this
reporter show that metformin reduces OvCa CM-induced PHD
activity in HPMCs, but not in the presence of succinate
(Figure 4F). Furthermore, the overexpression of SUCLG2 in
HPMCs (Figure S4D) resulted in a striking induction of HIF1a,
and in this setting, metformin no longer reduced HIF1a expres-
sion (Figure 4G). Finally, in the OvCa cohort, patients taking met-
formin for diabetes had lower SUCLG2 expression in omental
metastases, but not in primary tumors, compared to OvCa pa-
tients without diabetes not taking metformin (Figure 4H). These
findings suggest that metformin inhibits OvCa-driven stabiliza-
tion of HIF1a in HPMCs, in part by preventing themetabolic inac-
tivation of PHD by succinate downstream of the TCA enzyme,
SUCLG2.
Metformin Inhibits TGF-b-Driven Metabolic
Upregulation of HIF1a via PHD Inhibition
The previous results focused on the effect of metformin on meso-
thelial cells, but it was still unclear what, if any, signals originating
fromOvCa cells are targetedby the drug. To address this question
in an unbiased manner, we performed a proteomics analysis of
OvCa cells treatedwithmetformin. The results established several
signaling pathways affected by metformin, including TGF-b,
its cognate receptor (TGF-bR2), and tumor necrosis factor a
(TNF-a) (Figure 5A; Table S5). Based on previous studies showing
that TGF-b1 activates HPMCs (Kenny et al., 2014; Shin et al.,
2017), we tested whether TGF-b signaling was involved in the ef-
fect of metformin on HIF-dependent reprogramming of HPMCs
byOvCacells. In threedifferentOvCacell lines,metformin reduced
the expression of TGF-b2R and the activation of the downstream
target of TGF-b SMAD2/3 (Figures 5B and S5A), as well as TGF-
b1 mRNA expression (Figures 5C and S5B). The induction of
SMAD2/3 phosphorylation in HPMCs by OvCa co-culture was
blocked by metformin or a TGF-bR inhibitor, while neither agent
affected TGF-bR2 expression (Figure 5D). In addition, in all three
OvCa cell lines, the inhibition of OvCa invasion by metformin
pretreatment of HPMCs was reversed by recombinant human
TGF-b1 (Figures 5E and S5C).
Building on the findings in Figure 4, we sought to understand
how the inhibition of TGF-b signaling in OvCa cells by metformin(G) Western blot of HIF1a expression. HPMCs were transfected with SUCLG2 an
blot from n = 3 patients in duplicate).
(H) SUCLG2 immunohistochemical staining in primary ovarian and omental m
non-diabetic patients with OvCa not taking metformin. Quantification of prima
metastasis (n = 12 and 8 for control and metformin, respectively) was performed u
magnification; scale bar represents 100 mm.
Data represent mean values ± SDs. #p < 0.09, *p < 0.05; $p < 0.05 in one but nowas involved in the stabilization of HIF1a by succinate in HPMCs.
TGF-b1 induced HIF1a protein expression in HPMCs and met-
formin reversed this effect, but not in the presence of succinate
(Figure 5F). To understand this further, we once again used a
GFP reporter of the HIF1a ODD domain. The results show that
TGF-b1 decreased PHD activity in HPMCs, as indicated by the
accumulation of its target ODD-GFP and that metformin
reversed this effect. Again, in the presence of succinate, metfor-
min was unable to overcome the effect of TGF-b1 on PHD activ-
ity (Figure 5G). Complementing this finding, when SUCLG2 was
overexpressed in HPMCs, metformin no longer inhibited HIF1a
expression induced by TGF-b1 (Figure 5H). These findings indi-
cate that in addition to targeting HPMCs, metformin targets
OvCa cells by inhibiting TGF-b1.
DISCUSSION
Emerging evidence indicating that the TME is critically important
for tumor growth (Joyce and Pollard, 2009) presents the oppor-
tunity for therapeutic strategies directed against tumor-
promoting cross-talk between the stroma and cancer cells. In
the present study, we report that metformin makes the TME
inhospitable to OvCa by interrupting bidirectional signaling be-
tween tumor and mesothelial cells. We had previously shown
that metformin prevents OvCa tumor growth in a xenograft
mouse model (Lengyel et al., 2015) and reduces the number of
peritoneal and omental OvCa implants in a syngeneic mouse
model (Litchfield et al., 2015). Although no mouse model of
OvCa accurately recapitulates human disease and each model
has unique limitations (Garson et al., 2012), the findings in our
early studies suggested that metformin could alter both the
omental stroma and the tumor cells. The findings reported here
add to these studies by defining a mechanism whereby metfor-
min targets theOvCa TMEby inhibiting OvCa-inducedmetabolic
reprogramming of mesothelial cells, resulting in decreased stro-
mal HIF1a signaling, thereby reducing OvCa invasion (Figure 6).
With the goal of defining how metformin targets pro-tumori-
genic reprogramming in OvCa TME, we used several integrated
unbiased approaches focused on both tumor and mesothelial
cells. The findings show that exposure of mesothelial cells to
OvCa represses PHD enzymatic activity in mesothelial cells, re-
sulting in increased HIF1a stabilization.Metformin prevented this
OvCa-induced HIF1a signaling in mesothelial cells. The effect of
metformin on PHD activity and HIF1a expression in mesothelial
cells was directly related to a decreased production of TCA inter-
mediates. This finding in OvCa-naive HPMCs complements our
finding in 2016 that TCA intermediates are decreased in tumors
from OvCa patients taking metformin for diabetes (Liu et al.,
2016). The integrated metabolomic and proteomic pathway
analysis reported here indicates that the inhibition of the TCAd then treated with TYKnu OvCa CM ±metformin (1 mM, 48 h) (representative
etastasis from OvCa patients with diabetes using metformin compared to
ry tumor (n = 15 and 17 for control and metformin, respectively) or omental
sing ImageScope software. Images are representative and were taken at 203
t both patients tested; n.s., not significant.
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Figure 5. Metformin Targets OvCa TGF-b1 Signaling to Inhibit HIF1a Stabilization in HPMCs
(A) Proteomics. MS of proteins extracted from DOV13 OvCa cells treated with metformin (1 mM, 72 h) were analyzed using a two-sided t test. Color gradient
indicates the density of the distribution, with green dots as outer 5%. Proteins related to the TGF-b pathway are annotated for comparison. Top pathways
regulated by metformin were determined by one-dimensional pathway enrichment analysis using FDR <0.02.
(B) Western blot of TGF-b-related proteins in DOV13 cells ±metformin (1 mM, 72 h) (representative blot from n = 2 experiments with 2 biological replicates each).
(C) qRT-PCR of TGF-b1 mRNA expression in DOV13 OvCa cells ± metformin treatment (1 mM, 72 h) (n = 2 samples per group in duplicate).
(D) Western blot of TGF-b-related proteins in HPMCs co-cultured with TYKnu OvCa cells ± metformin (1 mM, 48 h) (representative blot from n = 2 patients in
duplicate).
(E) Invasion of TYKnu OvCa cells (36 h) through the 3D model ±metformin pretreatment of HPMCs (250 mM for 72 h) ± recombinant human TGF-b1 protein (n = 2
patients in triplicate).
(F) Western blot of HIF1a expression in HPMCs treated with metformin (250 mM, 72 h) followed by the addition of recombinant human TGF-b1 protein (TGF-b1;
10 ng/mL) ± succinate (suc, 5 mM) (representative blot from n = 3 patients in duplicate).
(G) PHD activity using the ODD-GFP reporter construct. HPMCs expressing the ODD-GFP construct were treated with TYKnu OvCa CM ± metformin (1 mM) ±
succinate (suc, 5 mM) for 16 h. An increased GFP signal indicates depleted PHD activity (n = 2 patients in duplicate).
(H) Western blot of HIF1a expression. HPMCs were transfected with SUCLG2 and then treated with recombinant human TGF-b1 (10 ng/mL) ±metformin (1 mM,
48 h) (representative blot from n = 3 patients in duplicate).
Data represent mean values ± SDs. *p < 0.05 and **p < 0.01.
4094 Cell Reports 29, 4086–4098, December 17, 2019
Figure 6. Metformin Prevents Pro-tumori-
genic Bidirectional Signaling between Tu-
mor and Mesothelial Cells
Modulation of tumor-stromal crosstalk by metfor-
min inhibits OvCa tumor progression. Left: OvCa-
derived CM or TGF-b1 inhibits PHD activation in
mesothelial cells, resulting in HIF1a stabilization
and the subsequent induction of IL-8 and CCL2,
promoting tumor progression. Right: metformin
inhibits TGF-b1 from OvCa cells to impede tumor-
mesothelial cell crosstalk, thereby maintaining
PHD activity and the concomitant degradation of
HIF1a in mesothelial cells. This effect of metformin
is mechanistically linked to a reduction in SUCLG2
and succinate and ultimately prevents the stroma-
derived signaling required for OvCa colonization
and invasion of the omentum.cycle in mesothelial cells by metformin was primarily due to the
suppression of SUCLG2, a TCA enzyme with an undefined role
in cancer. SUCLG2 in mesothelial cells was also critically impor-
tant in the inhibition of HIF1a by metformin. These findings
demonstrate that metformin targets crosstalk in the ovarian
TME by suppressing cancer-cell-induced HIF1a stabilization in
mesothelial cells through the decreased production of TCA inter-
mediates. Hulea et al. (2018) found that in breast cancer in vitro,
the biguanide phenformin repressed succinate but induced
lactate, fumarate, and malate, suggesting that metabolic adap-
tations in response to biguanides result in increased glycolysis
and potentially reductive carboxylation. In the present study,
our finding that metformin caused the global repression of suc-
cinate and downstream TCA intermediates while glutamine
accumulated indicates an inhibition of oxidative metabolism.
These contrasting data demonstrate why, moving forward,
further metabolic assessment using biguanides at physiologic
doses in normoglycemic conditions is critically important.
By focusing on the TME, our approach overcomes the limita-
tions of prior studies that have focused on cancer cells in
isolation using high glucose cell culture conditions. Here, using
fresh human omental tissue ex vivo from patients taking metfor-
min for diabetes, we begin to understand more clearly the global
impact of metformin in the TME. The results show that in patients
using metformin for diabetes, there is a profound reduction in
the adhesion of OvCa cells to the omentum, the primary TME
of OvCa. Furthermore, using our 3D organotypic model in
normoglycemic culture conditions (5 mM glucose) and near-
physiologic doses (250 mM) of metformin, we identified the
molecular effects of the drug on the ovarian TME. We have pre-
viously shown that mesothelial cell-ECM interactions through
fibronectin play an essential role in adhesion and invasion of
OvCa cells to the omentum (Kenny et al., 2014); here, we identify
that CCL2 and IL-8 are cytokines that serve as important targets
of metformin in the TME. Consistent with a recent report by
Gao et al., showing that metformin represses nuclear factor kB
(NF-kB)-dependent IL-6 secretion in fibroblasts (Xu et al.,
2018), metformin reduced the induction of CCL2 and IL-8 in
the mouse omentum exposed to CM from ID8 OvCa cells with
wild-type p53, but not from p53 knockout cells. While a compre-hensive dissection of the role of p53 in the effect of metformin in
the TME is beyond the scope of the present study, it is an impor-
tant consideration in future work, as others have reported that
the inhibition of colon cancer cell growth by metformin is p53
dependent (Buzzai et al., 2007). Asmetformin progresses to clin-
ical use as a cancer therapeutic, we need to contend with the
fact that not all patients will respond to this treatment and we
will need to be able to identify a priori which patients should be
offered metformin. Previous reports have suggested that CCL2
and IL-8 receptor expression is upregulated in several cancers
(David et al., 2016; Yao et al., 2019). The findings reported here
merit further evaluation of these cytokines as predictive bio-
markers in ongoing metformin clinical trials.
Protection against stromal reprogramming may be an impor-
tant mechanism of action for metformin in cancer and other
conditions. In peritoneal fibrosis, metformin blocks the reprog-
ramming of peritoneal mesothelial cells by suppressing TGF-b
signaling (Shin et al., 2017). In the present study, we show that
the drug also targets TGF-b-dependent tumor-mesothelial cell
interaction in OvCa. The findings indicate that in the context of
metformin, TCA metabolism plays an important role in the effect
of TGF-b1 on PHD activity and HIF1a stability, adding to previ-
ous studies that suggest that TGF-b stabilizes HIF1a through
altered PHD expression (Marushima et al., 2011; McMahon
et al., 2006). The inhibition of HIF1a and CAIX by metformin in
the TME was also observed in patient samples. This suggests
that reduced HIF signaling in the omentummay be a mechanism
by which metformin could prevent cancer progression, as previ-
ous studies have shown that increased hypoxia in high-grade
serous OvCa (HGSOC) tumors was associated with worse
survival (Hynninen et al., 2006). The results presented here add
to the continuously growing understanding of the potential roles
of HIF signaling in the TME (Casazza et al., 2014), as our data
identify the importance of HIF signaling in mesothelial cells as
a critical process for OvCa progression that can be effectively
targeted using metformin.
In summary, while the story of metformin and cancer began
with the seed (the cancer cells), the findings reported here
show that the true path forward may actually lie in the soil
(the adjacent stromal cells). Further dissection of the effects ofCell Reports 29, 4086–4098, December 17, 2019 4095
metformin on tumor-stromal interactions in vivo will require the
use of improved preclinical models that recapitulate the physio-
logic events representing the progression of the disease. Ulti-
mately, the most rigorous test of the efficacy of metformin as a
cancer treatment and the effect of the drug on the TME lies
ahead in the results of prospective randomized clinical trials
that are testing metformin as a cancer treatment in patients
without diabetes and of the coupled tumor analysis, such as
our ongoing prospective randomized neoadjuvant clinical trial
in OvCa (ClinicalTrials.gov: NCT02122185).
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
CAIX Abcam 2D3, RRID:AB_2066533
SMAD2/3 BD Biosciences RUO; RRID:AB_398161
SMAD2/3 phospho-Ser465/467 CST D6G10; RRID:AB_2631089
HIF1a CST D2U3T; RRID:AB_2622225
HIF2a Novus Biologicals NB100; RRID:AB_10002593
TGFBR2 Abcam EPR14673; RRID:AB_2818975
Akt CST 9272; RRID:AB_329827
Akt phosphor-Ser473 CST D9E; RRID:AB_2315049
SUCLG2 ThermoFisher Scientific PA5-61289; RRID:AB_2648068
Vinculin Sigma VIN115; RRID:AB_477617
GAPDH CST 14C10; RRID:AB_561053
b-Actin Sigma AC15; RRID:AB_476744
Anti-Mouse IgG HRP-linked secondary CST 7076; RRID:AB_330924
Anti-Rabbit IgG HRP-linked secondary CST 7074; RRID:AB_2099233
Biological Samples
Primary omental tissue (for ex vivo studies,
and isolation of NOF/HPMC)
University of Chicago Department of
Obstetrics and Gynecology
https://www.uchicagomedicine.org/
conditions-services/obgyn
Ovarian cancer tissue micro-array University of Chicago Ovarian Cancer
Research Laboratory
https://obgyn.uchicago.edu/research/
lengyel-ovarian-cancer-laboratory
Chemicals, Peptides, and Recombinant Proteins
Low glucose (5mM) DMEM Life Technologies 11885-084
DMEM Corning 10-013-CV
RPMI1640 Corning 10-040-CV
FB-Essence VWR 10803-034
Penicillin/Streptomycin (100X) Corning 30-002-CI
MEM non-essential amino acids Corning 25-025-CI
MEM vitamins Corning 25-020-CI
Metformin Sigma D150959
AICAR Sigma A9978
Dorsomorphin (Compound C) Sigma P5499
N-oxalylglycine Sigma O9390
2-oxoglutarate Sigma 349631
Dimethyl succinate Sigma W239607
Q5 Site-Directed Mutagenesis Kit NEB E0554S
Lipofectamine 2000 ThermoFisher Scientific 11-668-500
Recombinant human IL-8 Peprotech 200-08M
Recombinant human CCL2 Peprotech 300-04
Recombinant human TGFb1 Life Technologies PHG9204
CXCR1/IL8RA neutralizing antibody R&D Systems MAB330-SP
LY364947 Tocris Bioscience 2718
Critical Commercial Assays
Quantikine ELISA – murine CXCL1 R&D Systems MKC00B
Quantikine ELISA – murine CCL2 R&D Systems MJE00B
(Continued on next page)
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Proteome Profiler Mouse Cytokine Array
Kit – Panel A
R&D Systems ARY006
Seahorse XF96 Cell Mito Stress Test Seahorse Bioscience 103015-100
Experimental Models: Cell Lines
TYKnu University of California Los Angeles Koneczny Laboratory
HeyA8 MD Anderson Cancer Center Mills Laboratory
DOV13 University of Illinois at Chicago Burdette Laboratory
Experimental Models: Organisms/Strains
C57BL/6NCrl Inbred Mice Charles River 027
Oligonucleotides
Please see Table S6 for oligonucleotide sequences.
Recombinant DNA
HA-HIF1a P402A/P564A-pcDNA3 Yan et al., 2007 Addgene: 338299
pHIV-ODD-EGFP-IRES-dTomato Bagnall et al., 2014 Addgene: 395015
SUCLG2 DNASU HsCD00445557
CXCR1 Sino Biological HG10856-NF
CCR2 Sino Biological HG16084-NF
EF1a-GFP-IRES-Puro (pEGIP) Zou et al., 2009 Addgene: 26777
Software and Algorithms
GraphPad Prism 7 GraphPad Software RRID: SCR_002798
FIJI [ImageJ] National Institutes of Health RRID:SCR_002285
Aperio ScanScope / Pixel Count v9 Leica Biosystems RRID: SCR_014311
Thermo Xcalibur ThermoFisher Scientific RRID: SCR_014593
MaxQuant Max Planck Institute RRID: SCR_014485
Perseus Max Planck Institute RRID: SCR_015753
Molecular Signatures Database Broad Institute, MIT RRID: SCR_016863
MetaboAnalyst McGill University RRID: SCR_015539
Other
Invasion transwell insert (8mm pore) ThermoFisher Scientific 353097
Co-culture transwell insert (0.4mm pore) Thomas Scientific 3450
Collagen type 1 [rat tail] Corning 354236
PureLink HiPure Plasmid Maxiprep Kit ThermoFisher Scientific K2100-06
IDEXX CellCheck IDEXX Bioresearch https://www.idexxbioanalytics.com/
cellcheckLEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Iris L.
Romero (iromero@bsd.uchicago.edu). All unique reagents generated during this study (CXCR1 V247N and CCR2 T94K plasmids)
will be made available upon reasonable request from the Lead Contact with a completed Materials Transfer Agreement.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patient Samples and Cultivation of Primary Fibroblasts and Mesothelial Cells
Whole omentum, normal omental fibroblasts (NOFs) and peritoneal mesothelial cells (HPMCs) were obtained from female patients
undergoing surgery for benign indications (e.g., abdominal cerclage, hysterectomy). Patient samples used for primary cell isolation,
as well as those designated as controls (e.g., for ex vivo experiments and in tissue microarray), were not diagnosed with diabetes or
on any drug used for diabetes (e.g., biguanides, sulfonylureas) at the time of surgery. Patient samples used for primary cell isolation or
ex vivo experiments also did not have a history of gynecologic cancer and did not present with abdominal inflammation at the time of
surgery. For patients with diabetes taking metformin, metformin (500-1000mg twice/day) was administered within 24h of omentale2 Cell Reports 29, 4086–4098.e1–e6, December 17, 2019
sample collection. Primary omental fibroblasts and mesothelial cells were extracted from omentum as previously described (Kenny
et al., 2014) andmaintained in standard RPMI supplemented with 20%FB-Essence (VWR) with 1%penicillin/streptomycin (Corning),
1%MEMnon-essential amino acids (Corning) and 1%MEMvitamins (Corning). Primary cells were passaged nomore than once prior
to performing experiments. Written informed consent was obtained as part of an approved IRB protocol at the University of Chicago,
Department of Obstetrics and Gynecology.
Human Subjects
Tumor samples from female patients with ovarian cancer were provided by the Human Tissue Resource Center at the University of
Chicago. Tumors were collected from patients undergoing debulking surgery performed by a gynecologic oncologist at the Univer-
sity of Chicago, Section of Gynecologic Oncology. Informed consent was obtained prior to surgery in accordance with IRB approval
by the University of Chicago.
Cell Lines
TYKnu, HeyA8 and DOV13 human OvCa cell lines and ID8murine OvCa cell lines were maintained in standard DMEM supplemented
with 10%FB-Essence (VWR)with 1%penicillin/streptomycin (GEHealthcare), 1%MEMnon-essential amino acids (Corning) and 1%
MEM vitamins (Corning). All OvCa cell lines were tested for mycoplasma and authenticated by short tandem repeat marker profiling
every 3-6 months (CellCheck, IDEXX Bioresearch, Columbia, MO).
Mouse Models
Female C57BL/6 mice (Charles River Laboratories, Wilmington, MA) were 8 weeks of age and weighed approximately 25 g at the
initiation of the study, and were housed in groups of 5 throughout the duration of the study. Mice were intraperitoneal (i.p.) injected
with OvCa conditioned media and sacrificed for omental harvesting as described below.
METHOD DETAILS
Reagents, Plasmids, and Cell Culture
All experiments were performed in low glucose (5mM glucose) DMEM (Corning, Corning, NY), with 10% FB-Essence (VWR Life Sci-
ence, Radnor, PA), 1% penicillin/streptomycin (GE Healthcare, Helsinki, Finland), 1%MEM non-essential amino acids and 1%MEM
vitamins (Corning). GFP was stably expressed in OvCa cells using EF1a-GFP-IRES-puro (Zou et al., 2009), a gift from Linzhao Cheng
obtained through Addgene (#26777), with selection using puromycin for several passages prior to further use. The constitutively
stable HIF1a (HA-HIF1alpha P402A/P564A-pcDNA3) plasmid, which cannot be hydroxylated by PHD to target VHL-linked ubiquiti-
nation and degradation of HIF1a, was a gift from William Kaelin (Yan et al., 2007) obtained through Addgene (#338299). The pHIV-
oxygen-dependent degradation (ODD) -EGFP-IRES-dTomato used to measure PHD activity was a gift from Violaine Se´e (Bagnall
et al., 2014) obtained through Addgene (#395015). SUCLG2 plasmid DNAwas obtained through DNASUPlasmid Repository (Arizona
State University, Tempe, AZ). CXCR1 and CCR2 plasmid DNA was obtained from Sino Biological (Beijing, China), and amino acid
substitutions were performed using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs (NEB), Beverly, MA) to generate
constitutively active mutants CXCR1-V247N (Han et al., 2012) and CCR2-T94K (Alvarez Arias et al., 2003), as detailed below. Trans-
fections were performed using 1mg plasmid with Lipofectamine 2000 purchased from ThermoFisher Scientific (Waltham, MA).
Metformin, AICAR, dorsomorphin (compound C), N-oxalylglycine, 2-oxoglutarate and dimethyl succinate were purchased from
Sigma Aldrich (St. Louis, MO) and prepared fresh prior to each experiment. Recombinant human IL-8 and CCL2 were obtained
from Peprotech (Rocky Hill, NJ), and recombinant human TGFb1 was obtained from ThermoFisher (Waltham, MA). Neutralizing anti-
body for CXCR1/IL8RA was obtained from R&D Systems (Minneapolis, MN). TGFBR1 inhibitor LY364947 was obtained from Tocris
Bioscience (Bristol, United Kingdom).
Conditioned Media and Co-culture Assays
TogenerateOvCaconditionedmedia (CM) for treatment ofHPMCs, TYKnucellswereplatedon10cmdishesat 1,000,000 cells per plate
and allowed to grow for 24h in standard growthmedia.Media was then replacedwith low glucose DMEM (supplemented with 10%FB-
Essence, 1% pen/strep, 1%MEM non-essential amino acids and 1%MEM vitamins; Corning) and cells were allowed to grow for 72h
prior to collection. Media was centrifuged and moved to a new tube to avoid cell debris, and stored at 20C until use. For analysis
of mesothelial cells co-cultured with OvCa cells, HPMCs were plated at 300,000 cells per well on a 6-well plate and TYKnu cells were
plated at 100,000 cells per transwell polyester membrane insert (0.4mmpore size, for use with 6-well plate; Corning) on a separate plate.
Cellswereculturedseparately for24hprior tomoving inserts toco-cultureTYKnuOvCacellswithHPMCs for48h.Treatments forCMand
co-culture experiments were performed as described in the figure legends. Conditionedmedia or transwell insert containing OvCa cells
was then discarded and HPMCs were lysed and prepared for western blot or proteomics, as described below.
Invasion Assay
OvCa cell invasion through 3D organotypic culture was performed as described previously (Kenny et al., 2009). Briefly, 15mg of collagen
type 1 (Corning) in 200mLwas added to 8mmpore transwell inserts (for usewith 24-well plates) and allowed to set overnight. Inserts wereCell Reports 29, 4086–4098.e1–e6, December 17, 2019 e3
decanted and washed once briefly with 1X PBS, and then 4,000 NOFs were plated and allowed to adhere for 2h prior to seeding 20,000
HPMCs. Stromal cells were then allowed to grow for an additional 24h. Following stromal cell culture, media was removed and GFP-
tagged HeyA8 cells (60,000), GFP-tagged TYKnu (100,000) or GFP-tagged DOV13 (100,000) cells were seeded in serum-free low-
glucose DMEM (using 300mL per insert). OvCa cells were allowed to invade through the 3D culture for 15h (HeyA8) or for 36h (TYKnu
and DOV13). Low-glucose DMEM containing 10% FB-Essence was used as a chemoattractant in the lower compartment (700mL per
well), and serum free low-glucose DMEM was used for negative controls. Transwell inserts were then inverted and scraped using
Q-tip to remove stromal cells and OvCa cells that had not migrated, fixed in 4% formaldehyde for 5min and then washed with 1X
PBS for 5min. GFP of cancer cells was imaged using a Nikon Eclipse Ti2 (Nikon Inc., Melville, NY) with 3 images per insert. OvCa cell
GFPwas thenmanually counted using FIJI/ImageJ software (NIH, Bethesda, MD), themean number of OvCa cells per insert was quan-
tified, and then the average number of cells invadedper groupwas statistically analyzed. For pretreatmentwithmetformin, eachcell type
was treated individually for 72hwith 250mMmetformin prior to formation of the 3Dmodel;metforminwas not present during the invasion
assay. All other treatments were added at the time of OvCa seeding at the doses indicated.
Cytokine Measurement of Murine Omentum
To generate conditioned media (CM), wild-type or ID8 p53/murine tumor cells (Walton et al., 2016) were seeded at 1,000,000 per
15cm dish and allowed to grow for 24h prior to replacement of media with 15mL serum-free DMEM. CM was then collected at 48h,
concentrated using centrifugal filter units with 3K membrane (Millipore, Burlington MA) by centrifugation at 4000rpm for 1h at 4C,
and then the top portion was collected and used fresh per experiment at each time point indicated. Female C57BL/6 mice (Charles
River Laboratories) were treated with 300mg/kg metformin in drinking water (p.o., ad libitum) for 3 weeks, with the treatment water
replaced every other day, prior to intraperitoneal (i.p.) injection of 500mL ID8 CM. To capture both early/intermediate and delayed/late
cytokine production of the murine omentum, mice were injected i.p. with ID8 CM at both 4h and 72h (Bisiaux et al., 2017) prior to
sacrifice. Injection of CM, rather than tumor cells, was used specifically in order to isolate cytokines originating from themurine omen-
tum. Omental tissuewas harvested, immediately frozen at80Cand stored until preparation for cytokine array or ELISA. Expression
of murine omental cytokines were assessed using the Proteome Profiler Mouse Cytokine Panel A (R&D Systems), using twomice per
group on separate membranes with each cytokine in duplicate per membrane. Samples were prepared and assayed according to
manufacturer’s instructions. Protein expression was analyzed using FIJI/ImageJ (NIH) by quantifying the area under the curve
(AUC). Potential candidates of metformin’s action were identified as cytokines that had both consistent induction from ID8 CM as
well as repression back toward baseline expression level with metformin treatment. For validation of omental CXCL1 and CCL2
expression, using eight mice per group, mouse CXCL1/KC and CCL2/MCP-1 Quantikine ELISA kits were used according to manu-
facturer’s instructions (R&D Systems) with each sample run in duplicate. Round-bottom Eppendorf tubes each containing a 5mm
stainless steel bead (QIAGEN, Germantown MD) were pre-chilled on dry ice for 15min prior to addition of mouse omentum; samples
were chilled on dry ice for an additional 30min. Samples were then moved to TissueLyser LT (QIAGEN) and allowed to thaw for 2min
prior to addition of 250mL lysis buffer (100mM Tris/HCl [pH 7.4], 150mM NaCl, 1mM EDTA, 0.5% sodium deoxycholate, 1% Triton
X-100; diluted 1:2 in 1X PBS and supplemented with phosphatase/protease inhibitors immediately prior to use) and homogenization
at 50 oscillations/second for 5min (QIAGEN). All animal procedures were approved by the University of Chicago IACUC and were in
accordance with the University of Chicago’s policies on the care, welfare, and treatment of laboratory animals.
Omental Explant Ex Vivo Adhesion, Colonization, Invasion, and Protein Expression
Omental tissue for Western immunoblotting was immediately frozen at 80C prior to homogenization, which was carried out as
described above formurine omenta.Whole omental explants for ex vivo experimentswere incubated in lowglucoseDMEM immediately
following removal from the patient. Omental ex vivo adhesion/colonization experiments were completed by seeding HeyA8-GFP/
Luciferase or TYKnu-GFP (500,000) OvCa cells directly onto omental explant in a 96-well low adherence plate (ThermoFisher, Waltham,
MA). For examining omenta directly from patients who were on metformin, omental tissue from both nondiabetic controls and diabetic
patients on metformin undergoing surgery for benign indications were collected within 2h of each other. OvCa cells were seeded and
allowed to adhere for 1.5h; omenta were then washed with 1X PBS for 5min to remove non-adherent cells and GFP was imaged. For
treatment of omenta frombenign patients using exogenousmetformin, explantswere incubated in low glucoseDMEMwith 250mMmet-
formin for 72h prior to seeding OvCa cells. The cancer cells were allowed to adhere or colonize the omenta for 1.5h or 72h, respectively,
prior to washing with 1X PBS and imaging of GFP. For migration of OvCa toward explant, omental tissue was excised (50mg/well) and
treated for 72h in a 24-well plate; media was replacedwith serum free DMEM (containing 0.1%BSA) and thenGFP-taggedHeyA8 cells
(60,000) cellswere seededon top of 8mmpore transwell inserts and allowed to invade towardomental explant for 15h. In all experiments,
OvCa cell GFPwas imagedonNikon Eclipse Ti2 (Nikon) and analysiswas performed using at least 3 images per explant/insert, and then
averaged across replicate inserts to determine mean value per group.
Site-Directed Mutagenesis of CXCR1 and CCR2
Constitutively active mutants CXCR1-V247N and CCR2-T94K show basal receptor activity even in the absence of ligand and
demonstrate enhanced activity in response to ligand binding when compared to cells expressing wild-type receptor (Han et al.,
2012 and Alvarez Arias et al., 2003, respectively). CXCR1 and CCR2 ORF plasmid DNA (Sino Biological) were obtained and amino
acid substitutions were performed using the Q5 Site-Directed Mutagenesis Kit (NEB). Mutagenesis primers were designed usinge4 Cell Reports 29, 4086–4098.e1–e6, December 17, 2019
NEBaseChanger (NEB) and synthesized by Integrated DNA Technologies (IDT, Coralville, IA). Sequences are provided in the supple-
mentary Key Resources Table. The Q5 Hot Start High-Fidelity driven PCR was performed according to manufacturer’s instructions,
using an annealing temperature of 65 or 60C for CXCR1 or CCR2, respectively, for 30 s each cycle and then PCR product was
treated with KLD enzyme as directed. Following bacterial transformation, 10 colonies were selected for mini-prep and sequenced
at the University of Chicago DNA Sequencing Facility using 3730XL 96-capillary DNA sequencer (Applied Biosystems). Sequences
were selected based on alignment using NCBI BLAST (NIH) and plasmids with desired substitutions were amplified by PureLink
HiPure Plasmid Maxiprep Kit (ThermoFisher Scientific). CXCR1-V247N and CCR2-T94K were then transfected into GFP-tagged
TYKnu cells using Lipofectamine 2000 (ThermoFisher Scientific) and at 36h post-transfection stably selected using 50mg hygromycin
for 14d prior to use in functional assays.
Western Immunoblotting
Cell lysates were prepared in 125mL RIPA buffer (100mM Tris/HCl [pH 7.4], 150mM NaCl, 1mM EDTA, 0.1% (w/v) sodium dodecyl
sulfate, 0.5% sodium deoxycholate, 1% Triton X-100 and supplemented with phosphatase/protease inhibitors immediately
prior to use). Immunoblotting was performed as previously described (Lengyel et al., 2015). CAIX [2D3] antibody was purchased
from Abcam (Cambridge, MA), HIF2a [NB100] from Novus Biologicals (Littleton, CO), and SMAD2/3 [RUO] from BD Biosciences
(San Jose, CA). Vinculin [VIN115] and b-Actin [AC15] were from Sigma-Aldrich. HIF1a [D2U3T], TGFBR2 [EPR14673], SMAD2/3
pi-Ser465/467 [D6G10], Akt [9272], Akt pi-Ser473 [D9E], GAPDH [14C10] and HRP-linked secondary antibodies were from Cell
Signaling Technology (Beverly, MA). Gel electrophoresis was performed using 10-well 4%–20%Mini-PROTEAN TGXStain-Free Pro-
tein Gels (Bio-Rad, Hercules, CA) at 120V for 1h. Following transfer of proteins to Amersham Protran Premium Nitrocellulose Paper
(GE Healthcare), primary antibodies diluted at 1:1000 in 1X TBS-T were used overnight at 4C under agitation. Secondary antibodies
diluted at 1:2000 in 1X TBS-T and supplemented with 5% non-fat milk (LabScientific, Highlands, NJ) were used at room temperature
for 2h prior to developing using Clarity Western ECL Substrate (Bio-Rad). Membranes were then imaged using G:BOX Chemi XT4 for
up to 10min. FIJI/ImageJ (NIH) was used to perform densitometry to quantify the area under the curve (AUC).
Quantitative Reverse Transcription–Polymerase Chain Reaction
RNA was isolated from cells with the use of 1mL TRIzol (Invitrogen, Carlsbad, CA) and transcribed into cDNA using high-capacity
complementary DNA kit (Applied Biosystems,Waltham,MS). Quantitative real-time reverse transcriptase–polymerase chain reaction
(qRT-PCR) was performed as described (Sawada et al., 2008) using the Applied Biosystems 7500 Real Time PCR system. IL-8,
CCL2, TGFb1 and GAPDH Taqman probes were obtained from Applied Biosystems; CXCL1, CXCR1, CCR2, SUCLG2 and GAPDH
probes for SYBRGreen were obtained from IDT (sequences are provided in Key Resources Table). For each individual experiment, at
least 2 biological replicates were run in triplicate for each primer set. Relative levels of messenger RNA (mRNA) expression were
calculated by the 2-DDCT method with mRNA expression of experimental groups expressed relative to control, using GAPDH as
the housekeeping gene for normalization. Expression per data point or bar represents themean of biological replicates, with the error
bars indicating standard deviation between biological replicates.
Confocal Microscopy Analysis of Oxygen-Dependent Degradation-GFP to Detect PHD Inactivation
Prolyl hydroxylase (PHD) activity was measured using a GFP-tagged reporter construct for the HIF1a oxygen-dependent degrada-
tion (ODD) domain (Bagnall et al., 2014). HPMCswere plated at 300,000 cells per well in a 6-well dish and allowed to grow for 24h prior
to transduction with the pHIV-ODD-EGFP-IRES-dTomato lentiviral vector for 16h. At 48h post-infection, media was replaced with
low-glucose DMEMand treatments (metformin, succinate) were added. At 16h post-treatment, cells were washed with 1x PBS, fixed
with 4%paraformaldehyde for 5min, neutralizedwith 0.3Mglycine, and thenwashed again with 1x PBS. ODD-GFPwas imaged using
LSM 510META (Zeiss, Oberkochen, Germany) and analyzed with FIJI/ImageJ (NIH), with uninfected HPMCs and GFP-tagged cells
serving as negative and positive controls, respectively.
Immunohistochemistry
Tissue microarrays were assembled from paraffin-embedded tumor blocks from patients with OvCa as previously described
(Sawada et al., 2007) under a protocol approved by the University of Chicago IRB. Following antigen retrieval, slides were blocked
with fetal bovine serum albumin (BSA, Sigma) prior to incubation with primary antibody. Carbonic Anhydrase IX (CAIX [2D3], Abcam)
was used at 1:200 in TBS-T overnight and succinate-CoA ligase beta (SUCLG2 [PA5-61289], ThermoFisher) was used at 1:2000 in
TBS-T overnight. Both were then incubated with HRP-linked secondary antibody at 1:5000 in TBS-T containing 1% BSA for 1h at
room temperature. Slides were scanned at 20x magnification using Aperio ScanScope XT (Leica Biosystems, Buffalo Grove, IL),
and intensity and frequency of antibody staining was determined using ImageScope (Leica). Aperio Pixel Count Algorithm (version
9) was used to quantify the frequency of high and low intensity staining of pixels across each sample per slide. The relative abundance
of each protein was defined by comparing the frequency of high intensity staining, to avoid background from potentially confounding
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Liquid Chromatography-Mass Spectrometry Proteomic Analysis
For proteomic analysis ofmesothelial cells co-culturedwithOvCa cells, HPMCswere plated at 150,000 cells per well on a 6-well plate
and OvCa cells were plated at 100,000 cells per transwell polyester membrane insert (0.4mm pore size, for use with 6-well plate;
Corning) on a separate plate. Cells were cultured separately for 24h prior to moving inserts to co-culture TYKnu OvCa cells with
HPMCs for 48h. For proteomic analysis of mesothelial cells alone, HPMCs from 5 separate patients not taking metformin were plated
at 150,000 cells per well in triplicate in a 6-well dish and allowed to grow for 48h prior to metformin exposure (1mM, 48h). For pro-
teomic analysis of OvCa cells alone, DOV13 cells were plated at 700,000 cells per well in triplicate per condition in 10cm dishes and
allowed to grow for 24h prior to treatment with metformin (1mM, 72h). Following treatments, cells were collected with a MS-suitable
lysis buffer (100mM Tris HCl, 40mM 2-chloroacetamide, 10mM Tris (2-carboxyethyl) Phosphine [TCEP], 1% [w/v] sodium deoxycho-
late; buffered to pH 8.5 and supplemented with phosphatase/protease inhibitors immediately prior to use) using 100mL per 100,000
cells. Q-Exactive HF mass spectrometer coupled to EASY-nLC 1000 HPLC system (ThermoFisher) was used to perform label-free
shotgun proteomics as previously described in detail (Coscia et al., 2016). Briefly, peptides were separated in buffer B (80% aceto-
nitrile, 0.5% formic acid) at 200nl/min-1 over 100min, with an isolation window of 2.2Th and resolution of 17,500 at m/z 200. For the
experiments analyzing HPMCs co-cultured with TYKnu cells ± metformin, 8,945 proteins were identified. For the experiment
analyzing DOV13 cells ± metformin, 10,608 proteins were identified. Data were acquired using Xcalibur software (ThermoFisher),
raw data were analyzed using MaxQuant (Cox and Mann, 2008) and statistical analyses were carried out using Perseus (MaxQuant
Software Suite (Tyanova et al., 2016); Max Planck Institute of Biochemistry, Martinsried, Germany). Using Perseus, LFQ Intensity data
were log transformed [log2(x)], categorically annotated per group, filtered by valid values (at least 2 of 3 samples per group required a
valid value per protein), missing values were imputed from normal distribution per column, and then volcano plots were generated
using two-sided t test to identify significantly altered proteins. Principal component analysis (PCA) was performed using category
enrichment in components (5 components) and the Benjamini-Hochberg cutoff method with FDR of 0.05. For each PCA plot,
each box represents an individual patient sample/replicate. For unsupervised hierarchical clustering, data were first normalized to
z-score and then analyzed using k-means preprocessing and Euclidean distances. Pathway enrichment for OvCa-exposed HPMCs
was assessed by using the Molecular Signatures Database (MSigDB, GSEA, UCSD Broad Institute, San Diego, CA). For proteomic
analysis of DOV13 cells, the 2D annotation enrichment algorithm was used (Cox and Mann, 2012).
Gas Chromatography-MS Metabolic Profiling
For steady-state analysis ofmetabolites, HPMCs from2 separate patientswere plated at 1,000,000 cells per 15cmdish in duplicate and
allowed to grow for 72h prior tometformin exposure (1mM, 48h). Cells were lifted using Trypsin EDTA (1X, 0.25%; ThermoFisher Scien-
tific) and then pelleted by centrifugation at 0.5rcf. for 3min. Cell pellets were flash frozen in liquid nitrogen and then prepared
for downstream mass spectrometric analysis, as described previously (Lai et al., 2018). The Agilent 6530 Accurate-Mass Q-TOF LC/
MS quadrupole analyzer and Agilent 6890 GC/MS (Agilent, Santa Clara, CA) were used to perform untargeted metabolomics. 617 me-
tabolites were identified in total, and of those 189 known metabolites were used in subsequent analyses. Comparisons of relative
abundance were performed using Perseus (Max Planck) as described above, and significantly altered metabolites were analyzed in
conjunction with proteomics data usingMetaboAnalyst Joint Pathway Analysis (metaboanalyst.ca)(Chong et al., 2018) to indicate path-
ways altered by metformin.
Extracellular Flux Analysis
TYKnu OvCa cells, NOFs and HPMCs were pretreated with metformin (250mM) for 72h prior to seeding 10,000 cells per well, with 4
replicates per group, on Seahorse XF96 custommicroplates. Cells were allowed to recover for 16h overnight prior tomeasurement of
oxygen consumption rate (OCR), an indicator of mitochondrial electron transport chain complex I activity, and analyzed by Seahorse
XFe96 Extracellular Flux Analyzer using the Cell Mito Stress Test Kit (Agilent), as described previously (Hart et al., 2015). OCR was
then normalized to total protein concentration as determined by bicinchoninic acid assay (ThermoFisher).
QUANTIFICATION AND STATISTICAL ANALYSIS
Specific analyses performed for each assessment are described in the figure legends. In all analyses, data were evaluated using a
one-way ANOVAwith post hoc Tukey, or two-tailed t test, as appropriate; p < 0.05 was considered statistically significant. Number of
biological replicates or animals used (n) is included in the Figure Legends per experiment. Sample sizes were determined based on
previous experience with each experiment. All statistical analyses were carried out using GraphPad Prism 7 (GraphPad Software,
La Jolla, CA) or Perseus.
DATA AND CODE AVAILABILITY
All data supporting the findings of this study are available within the paper, in the Figures S1, S5 and in the Tables S1, S2, S3, S4, S5,
and S6. Source data (e.g., representative Western immunoblots) are available from the Lead Contact upon reasonable request. All
supplementary figures and data are available online. No unique software or code was used in this study.e6 Cell Reports 29, 4086–4098.e1–e6, December 17, 2019
